Key Points
- Scott Ullem, Edwards Lifesciences' CFO, sold 13,000 shares on April 9 under a Rule 10b5‑1 plan at an average price of $80.04 for about $1.04M, reducing his stake by 24.67% to 39,699 shares (≈$3.18M).
- The company reported quarterly EPS of $0.58 (missed by $0.04) with revenue of $1.57B (+13.3% y/y), set Q1 2026 guidance of $0.700–0.760 EPS, and its stock trades around $79 with a 12‑month range of $66.77–$87.89 and a $45.6B market cap.
- Institutional investors own about 79.46% of Edwards Lifesciences, and analysts' consensus is a "Moderate Buy" with an average target price of $95.96 (3 Strong Buy, 16 Buy, 9 Hold).
Edwards Lifesciences Corporation (NYSE:EW - Get Free Report) CFO Scott Ullem sold 13,000 shares of Edwards Lifesciences stock in a transaction dated Thursday, April 9th. The stock was sold at an average price of $80.04, for a total transaction of $1,040,520.00. Following the transaction, the chief financial officer owned 39,699 shares of the company's stock, valued at approximately $3,177,507.96. The trade was a 24.67% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Edwards Lifesciences Stock Performance
Shares of EW opened at $79.11 on Friday. Edwards Lifesciences Corporation has a 12-month low of $66.77 and a 12-month high of $87.89. The stock has a market cap of $45.61 billion, a P/E ratio of 43.23, a PEG ratio of 2.13 and a beta of 0.95. The company has a 50-day moving average of $81.48 and a two-hundred day moving average of $81.91. The company has a current ratio of 3.72, a quick ratio of 3.09 and a debt-to-equity ratio of 0.06.
Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share for the quarter, missing analysts' consensus estimates of $0.62 by ($0.04). The company had revenue of $1.57 billion during the quarter, compared to analyst estimates of $1.54 billion. Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.The business's revenue was up 13.3% compared to the same quarter last year. During the same period last year, the firm earned $0.59 earnings per share. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. As a group, research analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.
Institutional Investors Weigh In On Edwards Lifesciences
Large investors have recently made changes to their positions in the business. JPL Wealth Management LLC acquired a new stake in shares of Edwards Lifesciences in the third quarter worth $25,000. MV Capital Management Inc. acquired a new stake in shares of Edwards Lifesciences in the fourth quarter valued at about $26,000. Kemnay Advisory Services Inc. acquired a new stake in shares of Edwards Lifesciences in the fourth quarter valued at about $27,000. True Wealth Design LLC grew its stake in shares of Edwards Lifesciences by 251.5% in the third quarter. True Wealth Design LLC now owns 362 shares of the medical research company's stock valued at $28,000 after buying an additional 259 shares in the last quarter. Finally, Kohmann Bosshard Financial Services LLC acquired a new stake in shares of Edwards Lifesciences in the fourth quarter valued at about $28,000. Institutional investors and hedge funds own 79.46% of the company's stock.
Wall Street Analyst Weigh In
Several research firms recently commented on EW. Canaccord Genuity Group set a $87.00 target price on Edwards Lifesciences and gave the company a "hold" rating in a research note on Wednesday, December 17th. Evercore reiterated an "outperform" rating and issued a $94.00 target price on shares of Edwards Lifesciences in a research note on Monday, January 5th. Wolfe Research upgraded Edwards Lifesciences from a "peer perform" rating to an "outperform" rating and set a $92.00 target price for the company in a research note on Wednesday, April 1st. UBS Group reaffirmed a "neutral" rating and set a $94.00 price target on shares of Edwards Lifesciences in a research report on Wednesday, February 4th. Finally, Stifel Nicolaus set a $110.00 price target on shares of Edwards Lifesciences and gave the stock a "buy" rating in a research report on Tuesday, January 20th. Three analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have assigned a Hold rating to the company's stock. Based on data from MarketBeat, Edwards Lifesciences currently has an average rating of "Moderate Buy" and a consensus target price of $95.96.
View Our Latest Analysis on EW
Edwards Lifesciences Company Profile
(
Get Free Report)
Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.
In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
